Intrauterine growth restriction

California Takes Decisive Action to Reduce Microplastics Pollution

Retrieved on: 
Thursday, February 24, 2022
Lung, Health, Plant, Compliance, Senate, Microplastics, Inflammation, Wetland, Research, COPA, Intrauterine growth restriction, Industry, Organization, Plastic, Adoption, Science, OPC, Comment, Leadership, River, Solution, Aquaculture, Synthetic fiber, Renewable energy, Sewage, Risk management

SACRAMENTO, Calif., Feb. 24, 2022 /PRNewswire/ -- In response to increasing concern about pervasive and persistent pollution caused by microplastics, the California Ocean Protection Council yesterday approved the first comprehensive microplastics strategy in the nation.

Key Points: 
  • SACRAMENTO, Calif., Feb. 24, 2022 /PRNewswire/ -- In response to increasing concern about pervasive and persistent pollution caused by microplastics, the California Ocean Protection Council yesterday approved the first comprehensive microplastics strategy in the nation.
  • This leading-edge Statewide Microplastics Strategy identifies early actions and research priorities to reduce microplastic pollution in California's marine environment.
  • "Microplastics are poisoning the ocean, both across the planet and off the California coast," said California Natural Resources SecretaryWadeCrowfoot.
  • This Statewide Microplastic Strategy provides a multi-year roadmap for California to take a national and global leadership role in managing microplastics pollution by utilizing a two-track approach to manage microplastic pollution.

LUCA Science Announces the Opening of a New Subsidiary in the UK and Expansion on the Collaboration With the University of Oxford on the Development of Novel Mitochondrial Therapeutics

Retrieved on: 
Wednesday, April 7, 2021
Research, Baby, Maternity, Genetics, Biotechnology, University, Pharmaceutical, Consumer, Health, Science, Education, Branches of biology, Biology, Cell biology, Mitochondria, Human pregnancy, Cellular respiration, Mitochondrion, Intrauterine growth restriction, Bioenergetics

LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.

Key Points: 
  • LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.
  • LUCA Science UK will be based in Oxford.
  • LUCA Science is a pioneer in developing a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional tissues.
  • LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent.

LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women's & Reproductive Health, on the Development of Novel Therapeutics to Improve Bioenergetics for Intrauterine Growth Restriction (IUGR)

Retrieved on: 
Tuesday, September 29, 2020
Research, Women, Baby, Maternity, Biotechnology, University, Pharmaceutical, Consumer, Health, Science, Education, Articles, RTT, Anatomy, Embryology, Human pregnancy, Intrauterine growth restriction, Malnutrition, Placenta, Childbirth

This collaboration was instigated by Dr Yosuke Matsumiya, the UK project director for LUCA Science, who will be coordinating the research with the University of Oxford.

Key Points: 
  • This collaboration was instigated by Dr Yosuke Matsumiya, the UK project director for LUCA Science, who will be coordinating the research with the University of Oxford.
  • The largest global causes of IUGR are malnutrition and/or failure of the placenta to effectively transfer nutrition to the baby.
  • We are very excited to be working with LUCA Science to address one of the major obstacles in obstetric care.
  • LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent.

Research reveals potential care gap for pregnant women with lupus

Retrieved on: 
Friday, August 2, 2019
RTT, Health, Medicine, Women's health, Articles, Pregnancy, Miscarriage, Pre-eclampsia, Preterm birth, Childbirth, Systemic lupus erythematosus, Intrauterine growth restriction

Women with lupus have a higher risk of experiencing pregnancy-related complications like miscarriage, stillbirth, preeclampsia, eclampsia, preterm labour and fetal growth restriction.

Key Points: 
  • Women with lupus have a higher risk of experiencing pregnancy-related complications like miscarriage, stillbirth, preeclampsia, eclampsia, preterm labour and fetal growth restriction.
  • The findings of this research point to the importance of educating women with lupus who are pregnant, or planning to become pregnant, about the benefits and risks of medications during pregnancy.
  • "They may indicate a care gap that needs to be addressed by health care providers and an information gap for women with lupus."
  • Few prior studies have examined medication use in pregnant women with lupus and showed varying frequencies of use prior to conception, during pregnancy, and post-partum.

HealthMed Services Ltd., Announces Memorandum Of Understanding With Advanced Prenatal Therapeutics, Inc.

Retrieved on: 
Thursday, February 28, 2019
Embryology, Human pregnancy, Intrauterine growth restriction, Forward-looking statement

D said, "APT has several patents either granted or pending that cover a broad range of Apheresis technology for the treatment of preeclampsia.

Key Points: 
  • D said, "APT has several patents either granted or pending that cover a broad range of Apheresis technology for the treatment of preeclampsia.
  • Preeclampsia is a leading cause of prematurity and intrauterine growth restriction which leads to lifelong challenges for a baby.
  • Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts.
  • The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date forward looking statements are made.